Cyclobarbital Calcium

CHEMBL2106556 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
510.6 g/mol
LogP
Phase
4

A calcium salt form of cyclobarbital with the same barbiturate sedative properties as the parent compound. It has been used to treat sleep disorders and anxiety.

Molecular Weight

510.6000 g/mol

TPSA

163.00 Ų

Mechanism of Action

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC1(C2=CCCCC2)C(=O)[N-]C(=O)NC1=O.CCC1(C2=CCCCC2)C(=O)[N-]C(=O)NC1=O.[Ca+2]

InChI

InChI=1S/2C12H16N2O3.Ca/c2*1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;/h2*6H,2-5,7H2,1H3,(H2,13,14,15,16,17);/q;;+2/p-2

Molecular Formula

C24H30CaN4O6

HBD / HBA

2 / 6

Rotatable Bonds

4

Heavy Atoms

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A calcium salt form of cyclobarbital with the same barbiturate sedative properties as the parent compound. It has been used to treat sleep disorders and anxiety.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Cyclobarbital Calcium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2106556. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 13293232. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.